Flurizan program worries hurt Myriad's stock

Myriad Genetics' stock continues to fall as investors fear poor results from a late-stage study of Flurizan for Alzheimer's. A phase II study of the drug found that Flurizan didn't benefit those with a moderate form of the disease, and Myriad designed the Phase III trial to focus on those with mild Alzheimer's. Investors aren't wild about the approach. "In a rush to Phase III, Myriad has made several critical mistakes, in our view," said one analyst.

- read the report for more

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.